Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: LiPolymer who wrote (3539)	12/16/1999 12:06:00 AM
From: Joe	Read Replies (2) \| Respond to of 4140

For those that don't follow the YAHOO thread, you might find this post by laserdoc99 interesting. Joe NEVER SEE THIS STOCK UNDER 10 AGAIN by: laserdoc99 12/15/1999 10:12 pm EST Msg: 15908 of 15913 I will never post on this board again if this stock ever goes below 10. Island Bum, please do not post again as long as it is above 10. Every eye journal is filled with letters in the editorial section from ophthalmologists around the world complaining about the FDA panel. Typical letters note that the foreign ophthalmologists find the procedure extremely safe (probably the safest of all refractive procedures) and with great patient satisfaction and quick visual rehabilitation. They wonder what is wrong with our FDA panel to slow down the development of such an excellent technology. Combine this with the company's modification to seek approval for the reduction of hyperopia and I can not possibly see the panel denying approval. I have been buying this stock a lot in the 10 to 12 range. I have been holding the stock for about one year and probably should have bought more when it was down in the low single digits but at the time I did not know how long the FDA would take. Given the recent information and the new Lehman coverage I feel better buying the stock here and now then when it was around 4-6. If the stock does not get approval, the worst part will not be the large economic loss, but rather the disappointment at not being able to easily help so many of my patients. I think this is a very common sentiment among ophthalmologists presently and the panel understands this. For the life of me, I can not see how they will turn it down. One last point: I believe that VISX's influence (be it probably indirect) had a fair amount to do with the prior rejection. Now that VISX has a large black eye, I believe the panel will be even more open to newer technology. Will be attending the meeting and talking to my colleagues.